Smith+Nephew to Distribute SI-BONE’s iFuse TORQ TNT, Unlocks $4,136 Reimbursement
Smith+Nephew signed a distribution agreement with SI-BONE to carry the iFuse TORQ portfolio for pelvic fracture fixation and sacroiliac joint fusion, including the FDA Breakthrough Device-designated iFuse TORQ TNT. The TNT device qualifies for Medicare New Technology Add-on Payment of up to $4,136 per procedure.
1. Distribution Agreement Terms
Smith+Nephew has entered a distribution agreement with SI-BONE to include the iFuse TORQ portfolio—comprising iFuse TORQ TNT and standard implants—for percutaneous pelvic fracture fixation and sacroiliac joint fusion procedures within its Trauma and Extremities unit.
2. iFuse TORQ Portfolio Features
The iFuse TORQ TNT system is tailored to sacral and iliac anatomy, carries FDA Breakthrough Device Designation, and joins the broader iFuse TORQ line, offering differentiated solutions for high-impact trauma applications.
3. Financial and Strategic Impact
By leveraging its global commercial platform and SI-BONE’s established sales channels, Smith+Nephew aims to deepen surgeon engagement in high-frequency trauma procedures and capture additional reimbursement upside, potentially enhancing hardware revenues in upcoming quarters.